Corpusculum Leweyi

E Vicipaedia
Jump to navigation Jump to search
Corpuscula Leweyi. Regiones substantiae nigrae in morbi Parkinson aegroto cum corpusculis Leweyi et neuronis implicitis, magnificationes variae. Series superior, magnificatio sesxagesimuplus (60x): inclusiones intraneuronales alpha-synucleini ad corpuscula Leweyi formandos aggregatae. Series inferior, magnificatio vicesimuplus (20x): imagines neuronos implicatos atque corpuscula Leweyi rotunda magnitudinum variarum ostendunt.
Corpuscula Leweyi

Corpusculum Leweyi[1] est aggregatio proteinorum (alpha-synucleini[2]) morbosa intra cellularem ad morbum Parkinsonianum et dementiam cum corpusculis Leweyi pertinentes[3], morbus corpusculorum Leweyi dictus. Morbi corpusculorum Leweyi sunt morbus Parkinsonianus, dementia cum corpusculis Leweyi, imbecillitas autonomica pura.

Natura corpusculorum Leweyi[recensere | fontem recensere]

Corpusculum Leweyi corpusculum inclusionis[recensere | fontem recensere]

Crystal 128 up.png Commentatio principalis: Corpusculum inclusionis

Corpusculum inclusionis est substantia stabilis intracellularis, quae vel intra cytoplasmate vel intra nucleum (sive utrumque). Corpuscula Leweyi ex plus quam nonaginta proteinis, imprimis α-synucleino, constituta sunt. Aggregatio non solum in cytoplasmate somatis (notione corpusculum Leweyi sensu strictu) sed etiam in neurito (notione neuritum Leweyi) fit.

Morbus corpusculorum Leweyi[recensere | fontem recensere]

Notio morbi corpusculorum Leweyi ad spectrum morborum diversorum cum diffusione corpusculorum Leweyi late in systema nervosum refert. Exempla sunt morbus Parkinsonianus, dementia cum corpusculis Leweyi, imbecillitas autonomica pura. Omnes cum perturbationibus gastrointestinalibus coniuncti sunt, ut scientia novissime systema nervosum entericum investigat. Inter effectus ibidem videtur, ut textus oesophagi (imprimis tunicae muscularis propriae) progressum morbi indicet[4].

Corpora Leweyi et morbus Parkinson[recensere | fontem recensere]

In morbo Parkinson corpusculis Leweyi plus quam nonaginta producta genorum insunt[5], ut alpha-synucleinum, DJ-1, LRKK2, parkin, mitochondrialis PTEN inducta kinasis 1 (PINK-1), at etiam mitochondriorum enzyma, molecula systematis ubiquitini et proteasomatum, autophagiae, formationis aggresomatum. PINK-1 mitochondria protegit. Aggresomata sunt proteinorum non recte plicatorum aggregationes.

Diagnosis neuropathologica[recensere | fontem recensere]

Systemata classificationis[recensere | fontem recensere]

Adhuc diversa systemata morborum Leweyi edita sunt:

  • Stadia Braakiensia (2003)[6]
  • Consensus criteria secundum McKeith (2005)[7]
  • Consensus criteria secundum Leverenz (2008)[8]
  • Systema statuum unificatum secundum Beach (2009)[9]
  • Consensus criteria neuropathologica secundum Attems (2021)[10]

Consensus criteria 2021 secundum[recensere | fontem recensere]

Consensus criteria anni 2021 ad locos affectos referunt, si enim commutationes pathologicae in regiones inveniuntur has:

Quisque locus ita positivus aestimatur, ut primum signa histopathologica corpusculorum Leweyi cognoscantur[11].

Nexus interni

Notae[recensere | fontem recensere]

  1. Tretiakoff (1919) Contribution a L’étude de L’anatomie Pathologique de Locus Niger de Soemmerling. Université de Paris, Paris. Tretiakoff corpuscula Leweyi Corps de Lewy vocavit.
  2. De alpha-synucleino et morbo Parkinson (Anglice)
  3. Outeiro T. F., Koss D. J., Erskine D., Walker L., Kurzawa-Akanbi M., Burn D., Donaghy P., Morris C., Taylor J. P., (2019). "Dementia with Lewy bodies: an update and outlook". Molecular neurodegeneration 14 (1): 5 
  4. Tanei Z.-I., Saito Y., et al. (Ian 2021). "Lewy pathology of the esophagus correlates with the progression of Lewy body disease: a Japanese cohort study of autopsy cases". Acta neuropathologica 141 (1): 25-37 
  5. Wakabayashi K., Tanji K., et al. (Apr 2013). "The Lewy body in Parkinson's disease and related neurodegenerative disorders". Molecular neurobiology 47 (2): 495-508 
  6. Braak H., Del Tredici K., et al. (2003). "Staging of brain pathology related to sporadic Parkinson's disease". Neurobiology of aging 24 (2): 197-211 
  7. McKeith I. G., Dickson D. W., et al. (Dec 2005). "Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium". Neurology 65 (12): 1863-72 
  8. J. B., Hamilton R., et al. (Apr 2008). "Empiric refinement of the pathologic assessment of Lewy-related pathology in the dementia patient". Brain pathology 18 (2): 220-4 
  9. Beach T.G., Adler C. H., et al. (Iun 2009). "Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction". Acta neuropathologica 117 (6): 613-34 
  10. Attems J., Toledo J. B., et al. (Feb 2021). "Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study". Acta neuropathologica 141 (2): 159-172 
  11. {{cite journal ]authors=Fujishiro H, Ferman T. J., et al. |title=Validation of the neuropathologic criteria of the third consortium for dementia with Lewy bodies for prospectively diagnosed cases |journal=Journal of neuropathology and experimental neurology |year=2008 |month=Iul |volume=67 |issue=7 |pages=649-56 |url=https://pubmed.ncbi.nlm.nih.gov/18596548/}}
imago adenomatis serratae coloni Haec stipula ad pathologiam spectat. Amplifica, si potes!